TD Cowen raised the firm’s price target on Alnylam (ALNY) to $371 from $282 and keeps a Buy rating on the shares. The firm updated its ...

ALNY stock gains after submitting a regulatory application in the EU, seeking the approval of vutrisiran to treat ATTR ...

After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S.

TD Cowen analyst Ritu Baral maintained a Buy rating on Alnylam Pharma (ALNY – Research Report) today and set a price target of $371.00.

Alnylam's Yvonne Greenstreet, at #STATSummit, predicts vutrisiran will become multibillion-dollar product for ...

Scotiabank started coverage on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) in a research note issued to ...

That course has changed slightly. On Tuesday, Maraganore launched a start-up, City Therapeutics, that builds on his 20-year ...

New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...

− Type II Variation Submission Based on the Positive HELIOS-B Phase 3 Study in which Vutrisiran Significantly Reduced the Risk of Death and Cardiovascular Events Relative to Placebo – Alnylam ...

On Friday, H.C. Wainwright maintained a positive outlook on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY), reiterating a Buy rating and a $400.00 price target. The firm's confidence is anchored ...

Alnylam Pharmaceuticals ALNY has outperformed the market over the past 20 years by 13.16% on an annualized basis producing an ...